Last reviewed · How we verify

NCT05887206

Corneal Toxicity in Patients Treated by Belantamab Mafodotin

Completed Last updated 2 June 2023
What this trial tests

trial testing Collection of datas in Myeloma Multiple in 43 participants. Completed in 2 May 2023.

Timeline
2 May 2022
Primary endpoint
2 May 2023
2 May 2023

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Saint Etienne
StatusCompleted
Study typeOBSERVATIONAL
Enrollment43
Start date2 May 2022
Primary completion2 May 2023
Estimated completion2 May 2023
Sites10 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Who can join

18 and older, any sex, with Myeloma Multiple. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Belantamab Mafodotin is the first antibody conjugate targeting B-cell maturation antigen (BCMA) in relapsed or refractory multiple myeloma (RRMM). It is used in multiple myeloma refractory to an immunomodulatory drug or proteasome inhibitor and refractory and/or intolerant to an anti-CD38 monoclonal antibody. It has been found that the immunotherapy causes corneal side effects, Microcyst-like Epithelial Changes (MECs). They are round-shaped corneal inclusions that migrate from the peripheral cornea to the center, causing blurry vision, dryness and refractive shifts depending on their location and density.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Collection of datas

Trials testing the same drug.

Other recruiting trials for Myeloma Multiple

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Saint Etienne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05887206.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing